0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Tumor Immune Cell Therapy Market Research Report 2026
Published Date: 2026-03-16
|
Report Code: QYRE-Auto-28T17280
Home | Market Reports | Health| Health Conditions| Cancer
Global Tumor Immune Cell Therapy Market Research Report 2024
BUY CHAPTERS

Global Tumor Immune Cell Therapy Market Research Report 2026

Code: QYRE-Auto-28T17280
Report
2026-03-16
Pages:131
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Tumor Immune Cell Therapy Market

The global Tumor Immune Cell Therapy market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Cancer immune cell therapy is a treatment method that activates the function of the patient's own immune cells, thereby enhancing the immune cells' ability to attack cancer and inhibit cancer cells. In actual treatment, we extract immune cells involved in attacking cancer from the patient's blood, cancer tissue, ascites, and pleural effusion, proliferate, activate, and enhance their functions in vitro before returning them to the patient.
The North American market for Tumor Immune Cell Therapy is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Tumor Immune Cell Therapy is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The global market for Tumor Immune Cell Therapy in Hematological Tumors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.
Major global companies of Tumor Immune Cell Therapy include MEDINET Co, Erytech, Seta Clinic Group, Takeda, SBI Holdings, Oxford BioTherapeutics, Fate Therapeutics, Gilead Sciences, Novartis, Osiris, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Tumor Immune Cell Therapy market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Tumor Immune Cell Therapy. The Tumor Immune Cell Therapy market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Tumor Immune Cell Therapy market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Tumor Immune Cell Therapy manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Tumor Immune Cell Therapy Market Report

Report Metric Details
Report Name Tumor Immune Cell Therapy Market
Segment by Type
  • Immune Checkpoint Inhibitors
  • Chimeric Antigen Receptor T-cell Therapy
  • Tumor-Infiltrating Lymphocytes Therapy
  • Cancer Vaccines
  • Bispecific Antibodies
  • Cytokine Therapy
Segment by Application
  • Hematological Tumors
  • Solid Tumors
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company MEDINET Co, Erytech, Seta Clinic Group, Takeda, SBI Holdings, Oxford BioTherapeutics, Fate Therapeutics, Gilead Sciences, Novartis, Osiris, Vericel Corporation, Fujifilm Cellular Dynamics, JCR Pharmaceuticals, Beike Biotechnology, Golden Meditech, Guanhao Biotech, Beroni Group, Legend Biotech
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
  • Chapter 3: Provides a detailed view of the competitive landscape for Tumor Immune Cell Therapy companies, covering revenue share, development plans, and mergers and acquisitions.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
  • Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
  • Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
  • Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
  • Chapter 12: Key findings and conclusions of the report.

FAQ for this report

Who are the main players in the Tumor Immune Cell Therapy Market report?

Ans: The main players in the Tumor Immune Cell Therapy Market are MEDINET Co, Erytech, Seta Clinic Group, Takeda, SBI Holdings, Oxford BioTherapeutics, Fate Therapeutics, Gilead Sciences, Novartis, Osiris, Vericel Corporation, Fujifilm Cellular Dynamics, JCR Pharmaceuticals, Beike Biotechnology, Golden Meditech, Guanhao Biotech, Beroni Group, Legend Biotech

What are the Application segmentation covered in the Tumor Immune Cell Therapy Market report?

Ans: The Applications covered in the Tumor Immune Cell Therapy Market report are Hematological Tumors, Solid Tumors

What are the Type segmentation covered in the Tumor Immune Cell Therapy Market report?

Ans: The Types covered in the Tumor Immune Cell Therapy Market report are Immune Checkpoint Inhibitors, Chimeric Antigen Receptor T-cell Therapy, Tumor-Infiltrating Lymphocytes Therapy, Cancer Vaccines, Bispecific Antibodies, Cytokine Therapy

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Tumor Immune Cell Therapy Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Immune Checkpoint Inhibitors
1.2.3 Chimeric Antigen Receptor T-cell Therapy
1.2.4 Tumor-Infiltrating Lymphocytes Therapy
1.2.5 Cancer Vaccines
1.2.6 Bispecific Antibodies
1.2.7 Cytokine Therapy
1.3 Market by Application
1.3.1 Global Tumor Immune Cell Therapy Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Hematological Tumors
1.3.3 Solid Tumors
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Tumor Immune Cell Therapy Market Perspective (2021–2032)
2.2 Global Tumor Immune Cell Therapy Growth Trends by Region
2.2.1 Global Tumor Immune Cell Therapy Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Tumor Immune Cell Therapy Historic Market Size by Region (2021–2026)
2.2.3 Tumor Immune Cell Therapy Forecasted Market Size by Region (2027–2032)
2.3 Tumor Immune Cell Therapy Market Dynamics
2.3.1 Tumor Immune Cell Therapy Industry Trends
2.3.2 Tumor Immune Cell Therapy Market Drivers
2.3.3 Tumor Immune Cell Therapy Market Challenges
2.3.4 Tumor Immune Cell Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Tumor Immune Cell Therapy Players by Revenue
3.1.1 Global Top Tumor Immune Cell Therapy Players by Revenue (2021–2026)
3.1.2 Global Tumor Immune Cell Therapy Revenue Market Share by Players (2021–2026)
3.2 Global Top Tumor Immune Cell Therapy Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Tumor Immune Cell Therapy Revenue
3.4 Global Tumor Immune Cell Therapy Market Concentration Ratio
3.4.1 Global Tumor Immune Cell Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Tumor Immune Cell Therapy Revenue in 2025
3.5 Global Key Players of Tumor Immune Cell Therapy Head Offices and Areas Served
3.6 Global Key Players of Tumor Immune Cell Therapy, Products and Applications
3.7 Global Key Players of Tumor Immune Cell Therapy, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Tumor Immune Cell Therapy Breakdown Data by Type
4.1 Global Tumor Immune Cell Therapy Historic Market Size by Type (2021–2026)
4.2 Global Tumor Immune Cell Therapy Forecasted Market Size by Type (2027–2032)
5 Tumor Immune Cell Therapy Breakdown Data by Application
5.1 Global Tumor Immune Cell Therapy Historic Market Size by Application (2021–2026)
5.2 Global Tumor Immune Cell Therapy Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Tumor Immune Cell Therapy Market Size (2021–2032)
6.2 North America Tumor Immune Cell Therapy Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Tumor Immune Cell Therapy Market Size by Country (2021–2026)
6.4 North America Tumor Immune Cell Therapy Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Tumor Immune Cell Therapy Market Size (2021–2032)
7.2 Europe Tumor Immune Cell Therapy Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Tumor Immune Cell Therapy Market Size by Country (2021–2026)
7.4 Europe Tumor Immune Cell Therapy Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Tumor Immune Cell Therapy Market Size (2021–2032)
8.2 Asia-Pacific Tumor Immune Cell Therapy Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Tumor Immune Cell Therapy Market Size by Region (2021–2026)
8.4 Asia-Pacific Tumor Immune Cell Therapy Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Tumor Immune Cell Therapy Market Size (2021–2032)
9.2 Latin America Tumor Immune Cell Therapy Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Tumor Immune Cell Therapy Market Size by Country (2021–2026)
9.4 Latin America Tumor Immune Cell Therapy Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Tumor Immune Cell Therapy Market Size (2021–2032)
10.2 Middle East & Africa Tumor Immune Cell Therapy Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Tumor Immune Cell Therapy Market Size by Country (2021–2026)
10.4 Middle East & Africa Tumor Immune Cell Therapy Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 MEDINET Co
11.1.1 MEDINET Co Company Details
11.1.2 MEDINET Co Business Overview
11.1.3 MEDINET Co Tumor Immune Cell Therapy Introduction
11.1.4 MEDINET Co Revenue in Tumor Immune Cell Therapy Business (2021–2026)
11.1.5 MEDINET Co Recent Development
11.2 Erytech
11.2.1 Erytech Company Details
11.2.2 Erytech Business Overview
11.2.3 Erytech Tumor Immune Cell Therapy Introduction
11.2.4 Erytech Revenue in Tumor Immune Cell Therapy Business (2021–2026)
11.2.5 Erytech Recent Development
11.3 Seta Clinic Group
11.3.1 Seta Clinic Group Company Details
11.3.2 Seta Clinic Group Business Overview
11.3.3 Seta Clinic Group Tumor Immune Cell Therapy Introduction
11.3.4 Seta Clinic Group Revenue in Tumor Immune Cell Therapy Business (2021–2026)
11.3.5 Seta Clinic Group Recent Development
11.4 Takeda
11.4.1 Takeda Company Details
11.4.2 Takeda Business Overview
11.4.3 Takeda Tumor Immune Cell Therapy Introduction
11.4.4 Takeda Revenue in Tumor Immune Cell Therapy Business (2021–2026)
11.4.5 Takeda Recent Development
11.5 SBI Holdings
11.5.1 SBI Holdings Company Details
11.5.2 SBI Holdings Business Overview
11.5.3 SBI Holdings Tumor Immune Cell Therapy Introduction
11.5.4 SBI Holdings Revenue in Tumor Immune Cell Therapy Business (2021–2026)
11.5.5 SBI Holdings Recent Development
11.6 Oxford BioTherapeutics
11.6.1 Oxford BioTherapeutics Company Details
11.6.2 Oxford BioTherapeutics Business Overview
11.6.3 Oxford BioTherapeutics Tumor Immune Cell Therapy Introduction
11.6.4 Oxford BioTherapeutics Revenue in Tumor Immune Cell Therapy Business (2021–2026)
11.6.5 Oxford BioTherapeutics Recent Development
11.7 Fate Therapeutics
11.7.1 Fate Therapeutics Company Details
11.7.2 Fate Therapeutics Business Overview
11.7.3 Fate Therapeutics Tumor Immune Cell Therapy Introduction
11.7.4 Fate Therapeutics Revenue in Tumor Immune Cell Therapy Business (2021–2026)
11.7.5 Fate Therapeutics Recent Development
11.8 Gilead Sciences
11.8.1 Gilead Sciences Company Details
11.8.2 Gilead Sciences Business Overview
11.8.3 Gilead Sciences Tumor Immune Cell Therapy Introduction
11.8.4 Gilead Sciences Revenue in Tumor Immune Cell Therapy Business (2021–2026)
11.8.5 Gilead Sciences Recent Development
11.9 Novartis
11.9.1 Novartis Company Details
11.9.2 Novartis Business Overview
11.9.3 Novartis Tumor Immune Cell Therapy Introduction
11.9.4 Novartis Revenue in Tumor Immune Cell Therapy Business (2021–2026)
11.9.5 Novartis Recent Development
11.10 Osiris
11.10.1 Osiris Company Details
11.10.2 Osiris Business Overview
11.10.3 Osiris Tumor Immune Cell Therapy Introduction
11.10.4 Osiris Revenue in Tumor Immune Cell Therapy Business (2021–2026)
11.10.5 Osiris Recent Development
11.11 Vericel Corporation
11.11.1 Vericel Corporation Company Details
11.11.2 Vericel Corporation Business Overview
11.11.3 Vericel Corporation Tumor Immune Cell Therapy Introduction
11.11.4 Vericel Corporation Revenue in Tumor Immune Cell Therapy Business (2021–2026)
11.11.5 Vericel Corporation Recent Development
11.12 Fujifilm Cellular Dynamics
11.12.1 Fujifilm Cellular Dynamics Company Details
11.12.2 Fujifilm Cellular Dynamics Business Overview
11.12.3 Fujifilm Cellular Dynamics Tumor Immune Cell Therapy Introduction
11.12.4 Fujifilm Cellular Dynamics Revenue in Tumor Immune Cell Therapy Business (2021–2026)
11.12.5 Fujifilm Cellular Dynamics Recent Development
11.13 JCR Pharmaceuticals
11.13.1 JCR Pharmaceuticals Company Details
11.13.2 JCR Pharmaceuticals Business Overview
11.13.3 JCR Pharmaceuticals Tumor Immune Cell Therapy Introduction
11.13.4 JCR Pharmaceuticals Revenue in Tumor Immune Cell Therapy Business (2021–2026)
11.13.5 JCR Pharmaceuticals Recent Development
11.14 Beike Biotechnology
11.14.1 Beike Biotechnology Company Details
11.14.2 Beike Biotechnology Business Overview
11.14.3 Beike Biotechnology Tumor Immune Cell Therapy Introduction
11.14.4 Beike Biotechnology Revenue in Tumor Immune Cell Therapy Business (2021–2026)
11.14.5 Beike Biotechnology Recent Development
11.15 Golden Meditech
11.15.1 Golden Meditech Company Details
11.15.2 Golden Meditech Business Overview
11.15.3 Golden Meditech Tumor Immune Cell Therapy Introduction
11.15.4 Golden Meditech Revenue in Tumor Immune Cell Therapy Business (2021–2026)
11.15.5 Golden Meditech Recent Development
11.16 Guanhao Biotech
11.16.1 Guanhao Biotech Company Details
11.16.2 Guanhao Biotech Business Overview
11.16.3 Guanhao Biotech Tumor Immune Cell Therapy Introduction
11.16.4 Guanhao Biotech Revenue in Tumor Immune Cell Therapy Business (2021–2026)
11.16.5 Guanhao Biotech Recent Development
11.17 Beroni Group
11.17.1 Beroni Group Company Details
11.17.2 Beroni Group Business Overview
11.17.3 Beroni Group Tumor Immune Cell Therapy Introduction
11.17.4 Beroni Group Revenue in Tumor Immune Cell Therapy Business (2021–2026)
11.17.5 Beroni Group Recent Development
11.18 Legend Biotech
11.18.1 Legend Biotech Company Details
11.18.2 Legend Biotech Business Overview
11.18.3 Legend Biotech Tumor Immune Cell Therapy Introduction
11.18.4 Legend Biotech Revenue in Tumor Immune Cell Therapy Business (2021–2026)
11.18.5 Legend Biotech Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
 Table 1. Global Tumor Immune Cell Therapy Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
 Table 2. Key Players of Immune Checkpoint Inhibitors
 Table 3. Key Players of Chimeric Antigen Receptor T-cell Therapy
 Table 4. Key Players of Tumor-Infiltrating Lymphocytes Therapy
 Table 5. Key Players of Cancer Vaccines
 Table 6. Key Players of Bispecific Antibodies
 Table 7. Key Players of Cytokine Therapy
 Table 8. Global Tumor Immune Cell Therapy Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
 Table 9. Global Tumor Immune Cell Therapy Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 10. Global Tumor Immune Cell Therapy Market Size by Region (US$ Million), 2021–2026
 Table 11. Global Tumor Immune Cell Therapy Market Share by Region (2021–2026)
 Table 12. Global Tumor Immune Cell Therapy Forecasted Market Size by Region (US$ Million), 2027–2032
 Table 13. Global Tumor Immune Cell Therapy Market Share by Region (2027–2032)
 Table 14. Tumor Immune Cell Therapy Market Trends
 Table 15. Tumor Immune Cell Therapy Market Drivers
 Table 16. Tumor Immune Cell Therapy Market Challenges
 Table 17. Tumor Immune Cell Therapy Market Restraints
 Table 18. Global Tumor Immune Cell Therapy Revenue by Players (US$ Million), 2021–2026
 Table 19. Global Tumor Immune Cell Therapy Market Share by Players (2021–2026)
 Table 20. Global Top Tumor Immune Cell Therapy Players by Tier (Tier 1, Tier 2, and Tier 3), based on Tumor Immune Cell Therapy Revenue, 2025
 Table 21. Ranking of Global Top Tumor Immune Cell Therapy Companies by Revenue (US$ Million) in 2025
 Table 22. Global 5 Largest Players Market Share by Tumor Immune Cell Therapy Revenue (CR5 and HHI), 2021–2026
 Table 23. Global Key Players of Tumor Immune Cell Therapy, Headquarters and Area Served
 Table 24. Global Key Players of Tumor Immune Cell Therapy, Products and Applications
 Table 25. Global Key Players of Tumor Immune Cell Therapy, Date of General Availability (GA)
 Table 26. Mergers and Acquisitions, Expansion Plans
 Table 27. Global Tumor Immune Cell Therapy Market Size by Type (US$ Million), 2021–2026
 Table 28. Global Tumor Immune Cell Therapy Revenue Market Share by Type (2021–2026)
 Table 29. Global Tumor Immune Cell Therapy Forecasted Market Size by Type (US$ Million), 2027–2032
 Table 30. Global Tumor Immune Cell Therapy Revenue Market Share by Type (2027–2032)
 Table 31. Global Tumor Immune Cell Therapy Market Size by Application (US$ Million), 2021–2026
 Table 32. Global Tumor Immune Cell Therapy Revenue Market Share by Application (2021–2026)
 Table 33. Global Tumor Immune Cell Therapy Forecasted Market Size by Application (US$ Million), 2027–2032
 Table 34. Global Tumor Immune Cell Therapy Revenue Market Share by Application (2027–2032)
 Table 35. North America Tumor Immune Cell Therapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 36. North America Tumor Immune Cell Therapy Market Size by Country (US$ Million), 2021–2026
 Table 37. North America Tumor Immune Cell Therapy Market Size by Country (US$ Million), 2027–2032
 Table 38. Europe Tumor Immune Cell Therapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 39. Europe Tumor Immune Cell Therapy Market Size by Country (US$ Million), 2021–2026
 Table 40. Europe Tumor Immune Cell Therapy Market Size by Country (US$ Million), 2027–2032
 Table 41. Asia-Pacific Tumor Immune Cell Therapy Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 42. Asia-Pacific Tumor Immune Cell Therapy Market Size by Region (US$ Million), 2021–2026
 Table 43. Asia-Pacific Tumor Immune Cell Therapy Market Size by Region (US$ Million), 2027–2032
 Table 44. Latin America Tumor Immune Cell Therapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 45. Latin America Tumor Immune Cell Therapy Market Size by Country (US$ Million), 2021–2026
 Table 46. Latin America Tumor Immune Cell Therapy Market Size by Country (US$ Million), 2027–2032
 Table 47. Middle East & Africa Tumor Immune Cell Therapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 48. Middle East & Africa Tumor Immune Cell Therapy Market Size by Country (US$ Million), 2021–2026
 Table 49. Middle East & Africa Tumor Immune Cell Therapy Market Size by Country (US$ Million), 2027–2032
 Table 50. MEDINET Co Company Details
 Table 51. MEDINET Co Business Overview
 Table 52. MEDINET Co Tumor Immune Cell Therapy Product
 Table 53. MEDINET Co Revenue in Tumor Immune Cell Therapy Business (US$ Million), 2021–2026
 Table 54. MEDINET Co Recent Development
 Table 55. Erytech Company Details
 Table 56. Erytech Business Overview
 Table 57. Erytech Tumor Immune Cell Therapy Product
 Table 58. Erytech Revenue in Tumor Immune Cell Therapy Business (US$ Million), 2021–2026
 Table 59. Erytech Recent Development
 Table 60. Seta Clinic Group Company Details
 Table 61. Seta Clinic Group Business Overview
 Table 62. Seta Clinic Group Tumor Immune Cell Therapy Product
 Table 63. Seta Clinic Group Revenue in Tumor Immune Cell Therapy Business (US$ Million), 2021–2026
 Table 64. Seta Clinic Group Recent Development
 Table 65. Takeda Company Details
 Table 66. Takeda Business Overview
 Table 67. Takeda Tumor Immune Cell Therapy Product
 Table 68. Takeda Revenue in Tumor Immune Cell Therapy Business (US$ Million), 2021–2026
 Table 69. Takeda Recent Development
 Table 70. SBI Holdings Company Details
 Table 71. SBI Holdings Business Overview
 Table 72. SBI Holdings Tumor Immune Cell Therapy Product
 Table 73. SBI Holdings Revenue in Tumor Immune Cell Therapy Business (US$ Million), 2021–2026
 Table 74. SBI Holdings Recent Development
 Table 75. Oxford BioTherapeutics Company Details
 Table 76. Oxford BioTherapeutics Business Overview
 Table 77. Oxford BioTherapeutics Tumor Immune Cell Therapy Product
 Table 78. Oxford BioTherapeutics Revenue in Tumor Immune Cell Therapy Business (US$ Million), 2021–2026
 Table 79. Oxford BioTherapeutics Recent Development
 Table 80. Fate Therapeutics Company Details
 Table 81. Fate Therapeutics Business Overview
 Table 82. Fate Therapeutics Tumor Immune Cell Therapy Product
 Table 83. Fate Therapeutics Revenue in Tumor Immune Cell Therapy Business (US$ Million), 2021–2026
 Table 84. Fate Therapeutics Recent Development
 Table 85. Gilead Sciences Company Details
 Table 86. Gilead Sciences Business Overview
 Table 87. Gilead Sciences Tumor Immune Cell Therapy Product
 Table 88. Gilead Sciences Revenue in Tumor Immune Cell Therapy Business (US$ Million), 2021–2026
 Table 89. Gilead Sciences Recent Development
 Table 90. Novartis Company Details
 Table 91. Novartis Business Overview
 Table 92. Novartis Tumor Immune Cell Therapy Product
 Table 93. Novartis Revenue in Tumor Immune Cell Therapy Business (US$ Million), 2021–2026
 Table 94. Novartis Recent Development
 Table 95. Osiris Company Details
 Table 96. Osiris Business Overview
 Table 97. Osiris Tumor Immune Cell Therapy Product
 Table 98. Osiris Revenue in Tumor Immune Cell Therapy Business (US$ Million), 2021–2026
 Table 99. Osiris Recent Development
 Table 100. Vericel Corporation Company Details
 Table 101. Vericel Corporation Business Overview
 Table 102. Vericel Corporation Tumor Immune Cell Therapy Product
 Table 103. Vericel Corporation Revenue in Tumor Immune Cell Therapy Business (US$ Million), 2021–2026
 Table 104. Vericel Corporation Recent Development
 Table 105. Fujifilm Cellular Dynamics Company Details
 Table 106. Fujifilm Cellular Dynamics Business Overview
 Table 107. Fujifilm Cellular Dynamics Tumor Immune Cell Therapy Product
 Table 108. Fujifilm Cellular Dynamics Revenue in Tumor Immune Cell Therapy Business (US$ Million), 2021–2026
 Table 109. Fujifilm Cellular Dynamics Recent Development
 Table 110. JCR Pharmaceuticals Company Details
 Table 111. JCR Pharmaceuticals Business Overview
 Table 112. JCR Pharmaceuticals Tumor Immune Cell Therapy Product
 Table 113. JCR Pharmaceuticals Revenue in Tumor Immune Cell Therapy Business (US$ Million), 2021–2026
 Table 114. JCR Pharmaceuticals Recent Development
 Table 115. Beike Biotechnology Company Details
 Table 116. Beike Biotechnology Business Overview
 Table 117. Beike Biotechnology Tumor Immune Cell Therapy Product
 Table 118. Beike Biotechnology Revenue in Tumor Immune Cell Therapy Business (US$ Million), 2021–2026
 Table 119. Beike Biotechnology Recent Development
 Table 120. Golden Meditech Company Details
 Table 121. Golden Meditech Business Overview
 Table 122. Golden Meditech Tumor Immune Cell Therapy Product
 Table 123. Golden Meditech Revenue in Tumor Immune Cell Therapy Business (US$ Million), 2021–2026
 Table 124. Golden Meditech Recent Development
 Table 125. Guanhao Biotech Company Details
 Table 126. Guanhao Biotech Business Overview
 Table 127. Guanhao Biotech Tumor Immune Cell Therapy Product
 Table 128. Guanhao Biotech Revenue in Tumor Immune Cell Therapy Business (US$ Million), 2021–2026
 Table 129. Guanhao Biotech Recent Development
 Table 130. Beroni Group Company Details
 Table 131. Beroni Group Business Overview
 Table 132. Beroni Group Tumor Immune Cell Therapy Product
 Table 133. Beroni Group Revenue in Tumor Immune Cell Therapy Business (US$ Million), 2021–2026
 Table 134. Beroni Group Recent Development
 Table 135. Legend Biotech Company Details
 Table 136. Legend Biotech Business Overview
 Table 137. Legend Biotech Tumor Immune Cell Therapy Product
 Table 138. Legend Biotech Revenue in Tumor Immune Cell Therapy Business (US$ Million), 2021–2026
 Table 139. Legend Biotech Recent Development
 Table 140. Research Programs/Design for This Report
 Table 141. Key Data Information from Secondary Sources
 Table 142. Key Data Information from Primary Sources
 Table 143. Authors List of This Report


List of Figures
 Figure 1. Tumor Immune Cell Therapy Picture
 Figure 2. Global Tumor Immune Cell Therapy Market Size Comparison by Type (US$ Million), 2021–2032
 Figure 3. Global Tumor Immune Cell Therapy Market Share by Type: 2025 vs 2032
 Figure 4. Immune Checkpoint Inhibitors Features
 Figure 5. Chimeric Antigen Receptor T-cell Therapy Features
 Figure 6. Tumor-Infiltrating Lymphocytes Therapy Features
 Figure 7. Cancer Vaccines Features
 Figure 8. Bispecific Antibodies Features
 Figure 9. Cytokine Therapy Features
 Figure 10. Global Tumor Immune Cell Therapy Market Size by Application (US$ Million), 2021–2032
 Figure 11. Global Tumor Immune Cell Therapy Market Share by Application: 2025 vs 2032
 Figure 12. Hematological Tumors Case Studies
 Figure 13. Solid Tumors Case Studies
 Figure 14. Tumor Immune Cell Therapy Report Years Considered
 Figure 15. Global Tumor Immune Cell Therapy Market Size (US$ Million), Year-over-Year: 2021–2032
 Figure 16. Global Tumor Immune Cell Therapy Market Size, (US$ Million), 2021 vs 2025 vs 2032
 Figure 17. Global Tumor Immune Cell Therapy Market Share by Region: 2025 vs 2032
 Figure 18. Global Tumor Immune Cell Therapy Market Share by Players in 2025
 Figure 19. Global Tumor Immune Cell Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
 Figure 20. The Top 10 and 5 Players Market Share by Tumor Immune Cell Therapy Revenue in 2025
 Figure 21. North America Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 22. North America Tumor Immune Cell Therapy Market Share by Country (2021–2032)
 Figure 23. United States Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 24. Canada Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 25. Europe Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 26. Europe Tumor Immune Cell Therapy Market Share by Country (2021–2032)
 Figure 27. Germany Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 28. France Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 29. U.K. Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 30. Italy Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 31. Russia Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 32. Ireland Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 33. Asia-Pacific Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 34. Asia-Pacific Tumor Immune Cell Therapy Market Share by Region (2021–2032)
 Figure 35. China Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 36. Japan Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 37. South Korea Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 38. Southeast Asia Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 39. India Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 40. Australia & New Zealand Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 41. Latin America Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 42. Latin America Tumor Immune Cell Therapy Market Share by Country (2021–2032)
 Figure 43. Mexico Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 44. Brazil Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 45. Middle East & Africa Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 46. Middle East & Africa Tumor Immune Cell Therapy Market Share by Country (2021–2032)
 Figure 47. Israel Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 48. Saudi Arabia Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 49. UAE Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 50. MEDINET Co Revenue Growth Rate in Tumor Immune Cell Therapy Business (2021–2026)
 Figure 51. Erytech Revenue Growth Rate in Tumor Immune Cell Therapy Business (2021–2026)
 Figure 52. Seta Clinic Group Revenue Growth Rate in Tumor Immune Cell Therapy Business (2021–2026)
 Figure 53. Takeda Revenue Growth Rate in Tumor Immune Cell Therapy Business (2021–2026)
 Figure 54. SBI Holdings Revenue Growth Rate in Tumor Immune Cell Therapy Business (2021–2026)
 Figure 55. Oxford BioTherapeutics Revenue Growth Rate in Tumor Immune Cell Therapy Business (2021–2026)
 Figure 56. Fate Therapeutics Revenue Growth Rate in Tumor Immune Cell Therapy Business (2021–2026)
 Figure 57. Gilead Sciences Revenue Growth Rate in Tumor Immune Cell Therapy Business (2021–2026)
 Figure 58. Novartis Revenue Growth Rate in Tumor Immune Cell Therapy Business (2021–2026)
 Figure 59. Osiris Revenue Growth Rate in Tumor Immune Cell Therapy Business (2021–2026)
 Figure 60. Vericel Corporation Revenue Growth Rate in Tumor Immune Cell Therapy Business (2021–2026)
 Figure 61. Fujifilm Cellular Dynamics Revenue Growth Rate in Tumor Immune Cell Therapy Business (2021–2026)
 Figure 62. JCR Pharmaceuticals Revenue Growth Rate in Tumor Immune Cell Therapy Business (2021–2026)
 Figure 63. Beike Biotechnology Revenue Growth Rate in Tumor Immune Cell Therapy Business (2021–2026)
 Figure 64. Golden Meditech Revenue Growth Rate in Tumor Immune Cell Therapy Business (2021–2026)
 Figure 65. Guanhao Biotech Revenue Growth Rate in Tumor Immune Cell Therapy Business (2021–2026)
 Figure 66. Beroni Group Revenue Growth Rate in Tumor Immune Cell Therapy Business (2021–2026)
 Figure 67. Legend Biotech Revenue Growth Rate in Tumor Immune Cell Therapy Business (2021–2026)
 Figure 68. Bottom-up and Top-down Approaches for This Report
 Figure 69. Data Triangulation
 Figure 70. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Lukasiewicz Research Network